H. E. J. Research Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan.
Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan.
J Biomol Struct Dyn. 2022 Oct;40(16):7339-7350. doi: 10.1080/07391102.2021.1897045. Epub 2021 Mar 26.
Inhibition of dipeptidyl peptidase-IV (DPP-IV) has been identified as a promising approach for the treatment of type 2 diabetes mellitus (T2DM). Therefore, development of DPP-IV inhibitors with new chemical scaffold is of utmost importance to medicinal chemistry. In the present study, we identified benzophenone thio- and semicarbazone scaffolds as novel DPP-IV inhibitors. For that purpose, benzophenone thio- and semicarbazone were synthesized through a 2-step reaction. These newly synthetic derivatives were characterized by different spectroscopic techniques, including HREI-MS and NMR. whereas stereochemistry of the iminic bond was predicted by NOESY experiments. Thio- and semicarbazones derivatives were evaluated for their DPP-IV inhibitory potential and found to exhibit a good to moderate enzyme inhibitory activity. Most active and non-cytotoxic derivatives were further evaluated for their DPP-IV inhibitory potential in model. The binding sites as well as affinity of active compounds for DPP- IV enzyme were predicted by studies, and compared to a standard drug, sitagliptin. Pharmacophore studies of thio- and semicarbazones derivatives 1-29 suggest that substitution of aryl group, particularly a lipophilic substituents at C-4″ of benzene ring, and a hydroxyl at C-4' strongly influenced the DPP-IV inhibitory activity. Compound 9 showed the highest inhibitory activity (IC = 15.0 ± 0.6 µM), whereas compounds 10, 17, 12, 14 and 23 showed a moderate activity with IC values in the range of 28.9-39.2 µM. This study identifies thio- and semicarbazones as new classes of DPP-IV inhibitors which may translate into safe and effective therapeutics for a better management of type 2 diabetes.Communicated by Ramaswamy H. Sarma.
二肽基肽酶-4(DPP-4)抑制剂已被确定为治疗 2 型糖尿病(T2DM)的一种有前途的方法。因此,开发具有新化学结构的 DPP-4 抑制剂对药物化学至关重要。在本研究中,我们鉴定了苯并二酮硫代和缩氨基脲支架作为新型 DPP-4 抑制剂。为此,通过两步反应合成了苯并二酮硫代和缩氨基脲。这些新合成的衍生物通过不同的光谱技术进行了表征,包括 HREI-MS 和 NMR。而亚胺键的立体化学通过 NOESY 实验进行预测。硫代和缩氨基脲衍生物被评估为它们的 DPP-4 抑制潜力,并发现它们表现出良好到中等的酶抑制活性。最活跃和非细胞毒性衍生物进一步在模型中评估其对 DPP-4 的抑制潜力。通过研究预测了活性化合物与 DPP-4 酶的结合位点和亲和力,并与标准药物西他列汀进行了比较。硫代和缩氨基脲衍生物的药效团研究 1-29 表明,芳基的取代,特别是苯环上 C-4″的脂环取代基和 C-4'上的羟基,强烈影响 DPP-4 的抑制活性。化合物 9 表现出最高的抑制活性(IC = 15.0 ± 0.6 μM),而化合物 10、17、12、14 和 23 表现出中等活性,IC 值在 28.9-39.2 μM 范围内。这项研究确定了硫代和缩氨基脲作为新的 DPP-4 抑制剂类别,它们可能转化为安全有效的治疗方法,以更好地管理 2 型糖尿病。由 Ramaswamy H. Sarma 传达。